Detergent-Enhanced LAMP Detects African Trypanosome in CSF
By LabMedica International staff writers Posted on 12 Sep 2019 |
Image: A photomicrograph showing Trypanosoma brucei gambiense in a blood film. This parasitic protozoan species causes African trypanosomiasis (or sleeping sickness) in humans via the tsetse fly (Photo courtesy Alain G.C. Buguet).
Human African trypanosomiasis is a fatal disease, if untreated, spread by bloodsucking tsetse flies. These protozoan parasites first enter the lymph and blood to invade many organ systems, the early stage sleeping sickness.
Where human African trypanosomiasis (HAT) patients are seen, failure to microscopically diagnose infections by Trypanosoma brucei gambiense in blood smears and/or cerebrospinal fluid (CSF) in the critical early stages of the disease is the single most important factor in treatment failure.
An international team of scientist led by Johns Hopkins University School of Medicine (Baltimore, MD, USA) obtained 150 clinical samples from HAT patients. The team hypothesized that the enhanced sensitivity of detergent-enhanced loop-mediated isothermal amplification (LAMP) will allow for point of care (POC) detection of African trypanosomes in the CSF of HAT patients where the probability for detecting a single parasite or parasite DNA molecule in 1 μL of CSF sample is negligible by current methods.
The team used LAMP targeting the multicopy pan-T. brucei repetitive insertion mobile element (RIME LAMP) and the T. brucei gambiense 5.8S rRNA-internal transcribed spacer 2 gene (TBG1 LAMP). They tested 1 μL out of 20 μL sham or Triton X-100 treated CSFs from 73 stage-1 and 77 stage-2 HAT patients from the Central African Republic and 100 CSF negative controls. All LAMP reactions using commercially available kits that were previously optimized for reagent concentration, reaction time and temperature in real-time in a Loopamp real-time turbidimeter LA320C.
Under sham conditions, parasite DNA was detected by RIME and TBG1 LAMP in 1.4% of the stage-1 and stage-2 gambiense HAT CSF samples tested. After sample incubation with detergent, the number of LAMP parasite positive stage-2 CSF’s increased to 26%, a value which included the two of the four CSF samples where trypanosomes were identified microscopically. Unexpected was the 41% increase in parasite positive stage-1 CSF’s detected by LAMP.
The authors concluded that the study detected genomic trypanosome DNA in the CSF independent of the HAT stage and may be consistent with early CNS entry and other scenarios that identify critical knowledge gaps for future studies. Detergent-enhanced LAMP could be applicable for non-invasive African trypanosome detection in human skin and saliva or as an epidemiologic tool for the determination of human (or animal) African trypanosome prevalence in areas where chronically low parasitemias are present. The study was published on August 19, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Johns Hopkins University School of Medicine
Where human African trypanosomiasis (HAT) patients are seen, failure to microscopically diagnose infections by Trypanosoma brucei gambiense in blood smears and/or cerebrospinal fluid (CSF) in the critical early stages of the disease is the single most important factor in treatment failure.
An international team of scientist led by Johns Hopkins University School of Medicine (Baltimore, MD, USA) obtained 150 clinical samples from HAT patients. The team hypothesized that the enhanced sensitivity of detergent-enhanced loop-mediated isothermal amplification (LAMP) will allow for point of care (POC) detection of African trypanosomes in the CSF of HAT patients where the probability for detecting a single parasite or parasite DNA molecule in 1 μL of CSF sample is negligible by current methods.
The team used LAMP targeting the multicopy pan-T. brucei repetitive insertion mobile element (RIME LAMP) and the T. brucei gambiense 5.8S rRNA-internal transcribed spacer 2 gene (TBG1 LAMP). They tested 1 μL out of 20 μL sham or Triton X-100 treated CSFs from 73 stage-1 and 77 stage-2 HAT patients from the Central African Republic and 100 CSF negative controls. All LAMP reactions using commercially available kits that were previously optimized for reagent concentration, reaction time and temperature in real-time in a Loopamp real-time turbidimeter LA320C.
Under sham conditions, parasite DNA was detected by RIME and TBG1 LAMP in 1.4% of the stage-1 and stage-2 gambiense HAT CSF samples tested. After sample incubation with detergent, the number of LAMP parasite positive stage-2 CSF’s increased to 26%, a value which included the two of the four CSF samples where trypanosomes were identified microscopically. Unexpected was the 41% increase in parasite positive stage-1 CSF’s detected by LAMP.
The authors concluded that the study detected genomic trypanosome DNA in the CSF independent of the HAT stage and may be consistent with early CNS entry and other scenarios that identify critical knowledge gaps for future studies. Detergent-enhanced LAMP could be applicable for non-invasive African trypanosome detection in human skin and saliva or as an epidemiologic tool for the determination of human (or animal) African trypanosome prevalence in areas where chronically low parasitemias are present. The study was published on August 19, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Johns Hopkins University School of Medicine
Latest Molecular Diagnostics News
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders